FDA panel recommends Ferring's fecal transplant therapy

A panel of U.S. Food and Drug Administration advisers voted in favor of Ferring Pharmaceuticals' fecal transplant-based therapy to reduce recurrent infections caused by a bacteria known as C. difficile.